Login to Your Account

Samsung Bioepis wins nod for Europe's first Herceptin biosimilar

By David Ho
Staff Writer

Wednesday, November 22, 2017

HONG KONG – Samsung Bioepis Co. Ltd. has received approval in both South Korea and Europe for its Herceptin biosimilar. Known as Samfenet in South Korea and as Ontruzant in Europe, it marks the first Herceptin biosimilar to be approved by the European Commission.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription